Billions are funding
the future of longevity.
The world's top longevity companies — backed by Bezos, Thiel, Page, and Nobel laureates — are building therapies that may one day reverse aging. But none of them have a product a normal person can use today.
Eumaia is the platform that bridges the gap — making longevity science actionable right now, with the biomarkers you already have.
Layer 1
The Labs
Altos Labs, Calico, Unity Biotechnology, Juvenescence, and their peers are developing the drugs, gene therapies, and cellular reprogramming technologies that — in 5 to 20 years — may fundamentally alter how we age.
Layer 2
The Bridge — Eumaia
Eumaia applies the best of what already exists — PhenoAge, Zone 2 science, biomarker protocols, peptide stacks — to slow biological aging right now. No clinic. No waiting. No $25,000 invoice.
The core insight
"The people most likely to benefit from tomorrow's longevity therapies are the ones optimising their biology today."
When Altos Labs' reprogramming therapy is approved, when Unity's senolytics reach market, when gene therapy is mainstream — Eumaia's users will be first in line and healthiest going in. That's who we're building for.
The 11 Leading Longevity Companies
What they do, where they are, and when the world can access their work.
Altos Labs
ResearchBacked by: Jeff Bezos, Yuri Milner · Raised: $3B+
Cellular reprogramming — reversing cell age to a younger state using Yamanaka factors
Calico (Alphabet)
Research / Drug devBacked by: Google / Larry Page · Raised: $1.5B+
Molecular & cellular mechanisms of aging; partnership with AbbVie for drug development
Juvenescence
Clinical / Drug devBacked by: Jim Mellon, institutional · Raised: $295M+
Anti-aging prescription drugs and consumer products for age management and metabolic health
Insilico Medicine
Clinical trialsBacked by: Warburg Pincus, Qiming · Raised: $400M+
AI-accelerated drug discovery for aging-related diseases including fibrosis and Alzheimer's
AgeX Therapeutics
Research / Early clinicalBacked by: NYSE listed · Raised: $65M+
Tissue regeneration, stem cell research, and cellular immortality to reverse degenerative disease
Human Longevity Inc.
Live (premium)Backed by: Craig Venter, institutional · Raised: $300M+
Genomics + phenotypic data platform for predictive health — comprehensive in-clinic health intelligence
Unity Biotechnology
Phase 2 clinical trialsBacked by: Peter Thiel, Jeff Bezos · Raised: $300M+
Senolytic drugs — clearing senescent "zombie" cells that drive inflammation and tissue aging
BioViva
ExperimentalBacked by: Private · Raised: Undisclosed
Gene therapy targeting telomere extension and muscle loss — founder Elizabeth Parrish used herself as first patient
Methuselah Foundation
Funding / GrantsBacked by: Peter Thiel, philanthropists · Raised: $6M+ (non-profit)
Non-profit funding longevity research, prizes, and incubating mission-aligned ventures
SENS Research Foundation
Research grantsBacked by: Aubrey de Grey, donors · Raised: $50M+ (non-profit)
7 categories of aging damage repair — supporting rejuvenation biotechnology research globally
Gero
Research platformBacked by: Private · Raised: Series A
AI aging biomarker platform for identifying drug targets; dynamic resilience as aging measure
Eumaia vs. The Labs
Different layers. Not competitors — complementary.
| Capability | The Labs | Eumaia |
|---|---|---|
| Consumer access today | ||
| Biological age score | ||
| Personalised protocol library | ||
| Longevity simulator | ||
| AI expert advisor | ||
| Under $30/month | ||
| No clinical visit required | ||
| Drug / therapy development | ||
| Venture / institutional backing |
The closest comparison: Human Longevity Inc.
Of the 11 companies, Human Longevity Inc. is the only one with a live consumer product combining biomarker data with predictive health intelligence — the same core value proposition as Eumaia. HLI requires an in-clinic visit, a comprehensive genomic workup, and a bill of approximately $25,000 per year.
Eumaia delivers the core of what HLI does — biological age scoring, biomarker analysis, personalised protocol recommendations — starting at $0. No clinic. No genomic sequencing required. Works with blood work you already have.
$5B+
Raised by these 11 companies combined
0
Consumer products available today from the labs
$25K
Cost of the closest comparable service (HLI)
$0
Cost to start with Eumaia today
While the labs work on the future,
we help you survive into it.
Eumaia is not a biotech company. We are not racing to develop a drug. We are building the intelligence layer that turns today's best longevity science into a personalised, trackable, actionable plan — for everyone, not just those who can afford a $25,000 clinic visit.
60 seconds · No blood work needed to start · Free during beta